Acetylcholinesterase (AChE) inhibitors still comprise the majority of the marketed drugs for Alzheimer's disease (AD). The structural arrangement of the enzyme, which features a narrow gorge that separates the catalytic and peripheral anionic subsites (CAS and PAS, respectively), inspired the development of bivalent ligands that are able to bind and block the catalytic activity of the CAS as well as the role of the PAS in beta amyloid (Aβ) fibrillogenesis. With the aim of discovering novel AChE dual binders with improved drug-likeness, homo- and heterodimers containing 2H-chromen-2-one building blocks were developed. By exploring diverse linkages of neutral and protonatable amino moieties through aliphatic spacers of different length, a nan...
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, s...
Aiming at modulating two key enzymatic targets for Alzheimer's disease (AD), i.e., acetylcholinester...
Alzheimer’s disease (AD) is the most common neurodegenerative disorder characterized by progressive ...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
68 p.-17 fig.-1 tab. Chierrito, Talita P. C. et al.The lack of an effective treatment for Alzheimer'...
Alzheimer’s disease (AD) is a neurodegenerative disease that causes memory and cognitive decline as ...
Alzheimer’s disease (AD) is a neurodegenerative disease that causes memory and cognitive decline as ...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
The multifactorial nature of Alzheimer’s disease calls for the development of multitarget agents add...
none18In the last decade, the design of novel classes of inhibitors of the enzyme acetylcholinestera...
none18In the last decade, the design of novel classes of inhibitors of the enzyme acetylcholinestera...
none18In the last decade, the design of novel classes of inhibitors of the enzyme acetylcholinestera...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, s...
Aiming at modulating two key enzymatic targets for Alzheimer's disease (AD), i.e., acetylcholinester...
Alzheimer’s disease (AD) is the most common neurodegenerative disorder characterized by progressive ...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
68 p.-17 fig.-1 tab. Chierrito, Talita P. C. et al.The lack of an effective treatment for Alzheimer'...
Alzheimer’s disease (AD) is a neurodegenerative disease that causes memory and cognitive decline as ...
Alzheimer’s disease (AD) is a neurodegenerative disease that causes memory and cognitive decline as ...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
The multifactorial nature of Alzheimer’s disease calls for the development of multitarget agents add...
none18In the last decade, the design of novel classes of inhibitors of the enzyme acetylcholinestera...
none18In the last decade, the design of novel classes of inhibitors of the enzyme acetylcholinestera...
none18In the last decade, the design of novel classes of inhibitors of the enzyme acetylcholinestera...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
The need for developing real disease-modifying drugs against neurodegenerative syndromes, particular...
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, s...
Aiming at modulating two key enzymatic targets for Alzheimer's disease (AD), i.e., acetylcholinester...
Alzheimer’s disease (AD) is the most common neurodegenerative disorder characterized by progressive ...